Meeting
2017 ASCO Annual Meeting
A multicenter phase 4 geriatric assessment directed trial to evaluate gemcitabine +/- nab-paclitaxel in elderly pancreatic cancer patients (GrantPax).
Authors
Johannes Betge
Department of Medicine II, University Hospital Mannheim, Heidelberg University, Mannheim, Germany
Johannes Betge , Nicolai Haertel , Jing Chi-Kern , Sebastian Belle , Nadine Schulte , Martin Maenz , Ulrich Wedding , Matthias Philip Ebert
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Patient and Survivor Care
Track
Patient and Survivor Care
Sub Track
Geriatric Oncology
Clinical Trial Registration Number
NCT02812992
Citation
J Clin Oncol 35, 2017 (suppl; abstr TPS10124)
DOI
10.1200/JCO.2017.35.15_suppl.TPS10124
Abstract #
TPS10124
Poster Bd #
113a
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Associations of frailty with overall survival (OS) and functional decline among older adults with non–small-cell lung cancer (NSCLC) receiving chemotherapy, immunotherapy, and/or targeted therapy.
First Author: Howard Jinsoo Lee Jr.
Poster
2017 Gastrointestinal Cancers Symposium
Clinical outcome of modified FOLFIRINOX versus Gemcitabine plus nab-paclitaxel as first line chemotherapy in metastatic pancreatic cancer.
First Author: Kazuo Watanabe
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Second-line chemotherapy in elderly patients with advanced pancreatic cancer: A mono-institutional retrospective experience.
First Author: Giovanni Trovato
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Biweekly gemcitabine plus nab-paclitaxel as first-line therapy for older adult patients with unresectable pancreatic cancer: A prospective study.
First Author: Kenji Ikezawa